Vol 2 (August 25, 2024): AME Clinical Trials Review

Editorial Commentary 
Adjuvant immunotherapy in hepatocellular carcinoma: effective for Asian only, or for all patients?
Héloïse Bourien, Julien Edeline
AME Clinical Trials Review  
2024;
2:
62  
Editorial Commentary 
Maintenance strategies in first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer—one size does not fit all
Per Pfeiffer, Gabor Liposits, Line Tarpgaard
AME Clinical Trials Review  
2024;
2:
61  
Editorial Commentary 
Navigating the future of axillary surgery in HER2+ breast cancer: insights and opportunities for change
Joseph Dux, David Euhus
AME Clinical Trials Review  
2024;
2:
60  
Editorial Commentary 
Chemo-immunotherapy on localized gastroesophageal/gastric adenocarcinoma—hope or delusion?
Marcelo Porfirio Sunagua Aruquipa, Renata D’Alpino Peixoto
AME Clinical Trials Review  
2024;
2:
58  
Editorial Commentary 
Precision oncology in small-cell lung cancer: a tough nut to crack
Quincy S. C. Chu
AME Clinical Trials Review  
2024;
2:
56  
Editorial Commentary 
Exploring novel combinations in the treatment of relapsed ovarian cancer: the MEDIOLA trial results
Margherita Turinetto, Chiara Rognone, Giorgio Valabrega
AME Clinical Trials Review  
2024;
2:
54  
Editorial Commentary 
Combination and precision: ingredients for success in advanced gastric cancer
Eric Mehlhaff, Nataliya V. Uboha
AME Clinical Trials Review  
2024;
2:
52  
Editorial Commentary 
Can compartment-based complete mesocolic excision improve outcomes in patients with right colon cancer with metastatic D3 nodes?
Devesh S. Ballal, Avanish P. Saklani
AME Clinical Trials Review  
2024;
2:
51  
Editorial Commentary 
Nanoparticle-based drug delivery in advanced pancreatic ductal adenocarcinoma: is it time to deliver yet?
Zachary Coyne, Ronan Andrew McLaughlin, Harry Harvey, Jennifer J. Knox
AME Clinical Trials Review  
2024;
2:
50  
Editorial Commentary 
Personalized neoantigen vaccines for patients with advanced hepatocellular carcinoma
Carla Castro-Alejos, Pablo Sarobe
AME Clinical Trials Review  
2024;
2:
49  
Editorial Commentary 
Polo-like kinase 1 inhibitors in refractory colorectal cancer: deciphering the myth of synthetic lethality
Mariam Rojas, Laura Gonzalez, Marta Cascante, Joan Maurel
AME Clinical Trials Review  
2024;
2:
48  
Editorial Commentary 
Precision combination therapies: shaping the future management of advanced hepatocellular carcinoma?
Georgia Zeng, Mark Danta
AME Clinical Trials Review  
2024;
2:
47  
Editorial Commentary 
Multisegmented fully covered esophageal stent: a step to the side
Shamus R. Carr
AME Clinical Trials Review  
2024;
2:
46  
Editorial Commentary 
Xaluritamig: a first step towards a new target, new mechanism for metastatic prostate cancer
Ruben Raychaudhuri, Michael T. Schweizer, Jessica E. Hawley, Lawrence Fong, Evan Y. Yu
AME Clinical Trials Review  
2024;
2:
44  
Review Article 
Prediction of lymphatic invasion for patients with early gastric cancer: a review
Elfriede Bollschweiler, Patrick S. Plum
AME Clinical Trials Review  
2024;
2:
43